AG
IMDZ

Algert Global’s Immune Design Corp. IMDZ Stock Holding History

Algert Global’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-92,591
Closed -$120K – 450
2018
Q4 		$120K Buy
92,591
+77,500
+514% +$135K 0.03% 349
2018
Q3 		$52K Buy
15,091
+2,900
+24% +$10.9K 0.01% 338
2018
Q2 		$55K Buy
+12,191
New +$48.6K 0.01% 327

Other funds holding IMDZ

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
SAM
Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Algert Global's IMDZ Position: Q1 2019 in Review

Algert Global sold out of Immune Design Corp. (IMDZ) in Q1 2019, closing a stake of 92,591 shares — an estimated $120K sold.

Algert Global first reported a position in IMDZ in Q2 2018 and held it in 3 quarters. The position peaked at $120K in Q4 2018. 68 funds tracked by Wall St. Rank hold IMDZ as of Q1 2019.

  • Algert Global reported no remaining Immune Design Corp. position as of Q1 2019 after selling out during the quarter.
  • Algert Global sold 92,591 Immune Design Corp. shares in Q1 2019, an estimated $120K.
  • Algert Global first reported a position in Immune Design Corp. in Q2 2018 and held it in 3 quarters.
  • Algert Global's Immune Design Corp. position peaked at $120K in Q4 2018.
  • 68 funds tracked by Wall St. Rank held Immune Design Corp. as of Q1 2019.

Based on Algert Global's 13F filing for Q1 2019, filed 1 May 2019.